Video Series

The panel discusses considerations for payers as well as patient adherence to treatment in MDR HIV.

John L. Marshall, MD, provides insight into the SUNLIGHT study findings presented during the 2023 ASCO Gastrointestinal Cancers Symposium.

In their final thoughts, Drs Brinton, Baum and Michos provide insights on the trajectory of treatment in HoFH.

Medical experts discuss the unmet needs surrounding homozygous FH.

A panel of medical experts discuss diagnostic imaging surrounding DME and wet AMD.

Drs Coney, Luo, and Sheth discuss potential novel treatment mechanisms or options that we could see in the future with wet AMD and DME.

Therapy adjustments in MDR HIV are explored by Dr Sension.

Optimized background regimens are highlighted in the treatment approach for MDR HIV by Michael Sension, MD.

Drs Michos and Baum provide payer considerations regarding HoFH treatment pathways.

Considerations for authorization documentation in HoFH treatment are discussed.

Dr Haumschild leads a discussion highlighting goals of therapy and social determinants of health affecting MDR HIV diagnosis and treatment.

Veeral Sheth, MD, MBA, FACS discusses re-treatment in patients with wet AMD who have previously failed an anti-VEGF therapy.

A panel of experts explore burdens impacting patients diagnosed with MDR HIV.

Dr Coney expands on the role and impact of approved label dosing of faricimab.

The panel of experts provide their closing thoughts on the burden of disease in leukemia and lymphoma and the Bruton tyrosine kinase inhibitor landscape.

Callie Coombs, MD, and Roy Beveridge, MD, discuss the education needed for payers and physicians surrounding the use of the Bruton tyrosine kinase inhibitors.

A panel of experts provide their final thoughts on treating psoriasis across all skin phototypes.

A panel of experts provide their final thoughts on treating psoriasis across all skin phototypes.

Maria Lopes, MD, MS, and Amy McMichael, MD, discuss how payers can incentivize patients’ use of digital health tools to monitor the success or failure of treatment.

Drs Baum and Michos share insights on current barriers to access of care.

Evinacumab is highlighted as a new therapy for treating patients with homozygous FH.

Key opinion leaders discuss faricimab, its impact on the treatment landscape for wet AMD/DME, and what payers should look for when considering formulary positioning or utilization-management strategies.

Michael Sension, MD, provides insights on resistance mechanisms promoting MDR HIV.

Ryan Haumschild, PharmD, MS, MBA, opens a panel discussion surrounding the incidence and prevalence of multidrug-resistant (MDR) HIV.

Dr Coney discusses the variability of frequency dosing with anti-VEGF therapy in patients with wet AMD and DME, and Dr Sheth expands on Ang-2 and its contribution to the development of vascular instability in wet AMD.

Roy Beveridge, MD, and Brian Koffman, MD, explore how the Bruton tyrosine kinase inhibitors (BTKi) fit into value-based care models for oncology and the patient support offered to aid patients in gaining access to BTKis.

Brian Koffman, MD, and Roy Beveridge, MD, discuss the financial burdens of Bruton tyrosine kinase inhibitor therapy and considerations for oral therapy vs infusion therapy.

Amy McMichael, MD, provides an overview of the Psorcast app and how it can benefit treatment adherence for patients.

Bruce Sherman, MD, FCCP, FACOEM, and Maria Lopes, MD, MS, discuss how organizations can address disparities in care for psoriasis.

Experts discuss the effect and safety of lomitapide and evinacumab in treating patients with HoFH.